{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:21Z","timestamp":1790837061942,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012028","name":"Trombosestichting Nederland","doi-asserted-by":"publisher","award":["2018-03"],"award-info":[{"award-number":["2018-03"]}],"id":[{"id":"10.13039\/501100012028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtha.2023.05.024","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:04:39Z","timestamp":1686139479000},"page":"2509-2518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti\u2013\u03b22-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C"],"prefix":"10.1016","volume":"21","author":[{"given":"Tessa","family":"Noordermeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Chemlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna J.","family":"Jansma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vossa","family":"van der Vegte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.G.","family":"Schutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost C.M.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.05.024_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2012.09037.x","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"157","author":"Keeling","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.05.024_bib2","first-page":"98","article-title":"Diagnosing and treating antiphospholipid syndrome: a consensus paper","volume":"77","author":"Limper","year":"2019","journal-title":"Neth J Med"},{"key":"10.1016\/j.jtha.2023.05.024_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.05.024_bib5","first-page":"286","article-title":"The issue of the antiphospholipid antibody syndrome","volume":"12","author":"Oliveira","year":"2020","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.jtha.2023.05.024_bib6","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.autrev.2012.11.008","article-title":"Correct laboratory approach to APS diagnosis and monitoring","volume":"12","author":"Pengo","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2023.05.024_bib7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtha.2023.05.024_bib8","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jtha.2023.05.024_bib9","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1172\/JCI115926","article-title":"Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon \u03b22-glycoprotein I","volume":"90","author":"Roubey","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.05.024_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG\u2019s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0038-1648480","article-title":"Lupus anticoagulant activity is frequently dependent on the presence of \u03b22-glycoprotein I","volume":"67","author":"Oosting","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/jth.15241","article-title":"Anti-\u03b22-glycoprotein I and anti-prothrombin antibodies cause lupus anticoagulant through different mechanisms of action","volume":"19","author":"Noordermeer","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism","volume":"130","author":"Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.05.024_bib14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.thromres.2013.04.012","article-title":"Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study","volume":"132","author":"Zuily","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.05.024_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/MBC.0b013e32830f1b85","article-title":"Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C","volume":"19","author":"De Laat","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2023.05.024_bib16","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.ATV.0000168421.13467.82","article-title":"Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition","volume":"25","author":"Dahlb\u00e4ck","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.05.024_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jth.15199","article-title":"Insight into the hypercoagulable state of high-risk thrombotic APS patients: contribution of a\u03b22GPI and aPS\/PT antibodies","volume":"19","author":"Pontara","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2003-11-4085","article-title":"The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus","volume":"104","author":"Brouwer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib19","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1111\/j.1538-7836.2007.02734.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants","volume":"5","author":"Liest\u00f8l","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1373\/clinchem.2004.043414","article-title":"Acquired activated protein C resistance associated with IgG antibodies against \u03b22-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism","volume":"51","author":"Nojima","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2023.05.024_bib21","first-page":"1242","article-title":"Anti-domain I \u03b22-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T study","volume":"5","author":"Zuily","year":"2020","journal-title":"J\u00a0Appl Lab Med"},{"key":"10.1016\/j.jtha.2023.05.024_bib22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1055\/s-0041-1742083","article-title":"Interaction between antiphospholipid antibodies and protein C anticoagulant pathway: a narrative review","volume":"48","author":"Pengo","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib23","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1182\/blood.V93.8.2552","article-title":"Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V","volume":"93","author":"Thorelli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.24222","article-title":"Factor V Leiden","volume":"91","author":"Van Cott","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.05.024_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(05)80081-9","article-title":"Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study","volume":"342","author":"Koster","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.05.024_bib26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V85.6.1504.bloodjournal8561504","article-title":"High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)","volume":"85","author":"Rosendaal","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A\u00a0reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"De Visser","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib28","article-title":"Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti\u2013\u03b22-glycoprotein I antibody titers","volume":"7","author":"Noordermeer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib29","doi-asserted-by":"crossref","first-page":"33915","DOI":"10.1074\/jbc.M701123200","article-title":"The role of thrombin exosites I and II in the activation of human coagulation factor V","volume":"282","author":"Segers","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.05.024_bib30","doi-asserted-by":"crossref","first-page":"18735","DOI":"10.1016\/S0021-9258(17)32228-7","article-title":"Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa","volume":"269","author":"Shen","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.05.024_bib31","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/S0021-9258(19)69627-4","article-title":"The role of phospholipid and factor VIIIa in the activation of bovine factor X","volume":"256","author":"Van Dieijen","year":"1981","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.05.024_bib32","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1074\/jbc.M708036200","article-title":"Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va","volume":"283","author":"Tran","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.05.024_bib33","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1160\/TH04-03-0138","article-title":"Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis","volume":"92","author":"Kassis","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib34","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1182\/blood.V94.11.3839","article-title":"Inhibition of activated protein C anticoagulant activity by prothrombin","volume":"94","author":"Smirnov","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/joim.13022","article-title":"The antiphospholipid syndrome\u2014often overlooked cause of vascular occlusions?","volume":"287","author":"Svenungsson","year":"2020","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jtha.2023.05.024_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1055\/s-0037-1613265","article-title":"Anti-\u03b22-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of \u03b22-glycoprotein I to phospholipids","volume":"88","author":"Izumi","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jth.14765","article-title":"Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity","volume":"18","author":"Cattini","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2022.08.004","article-title":"Antiphospholipid syndrome: reversal of antiphosphatidylserine\/prothrombin-induced activated protein C resistance","volume":"218","author":"Pontara","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.05.024_bib39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH14-02-0122","article-title":"Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma?","volume":"112","author":"Pennings","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib40","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1021\/bi4006368","article-title":"Factor VII and protein C are phosphatidic acid-binding proteins","volume":"52","author":"Tavoosi","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2023.05.024_bib41","doi-asserted-by":"crossref","first-page":"13833","DOI":"10.1021\/bi960657q","article-title":"Role of divalency in the high-affinity binding of anticardiolipin antibody-\u03b22-glycoprotein I complexes to lipid membranes","volume":"35","author":"Willems","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.jtha.2023.05.024_bib42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1055\/s-0031-1297367","article-title":"Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective","volume":"37","author":"Lijfering","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0753-3322(96)84822-0","article-title":"Resistance to activated protein C: role in venous and arterial thrombosis","volume":"50","author":"Emmerich","year":"1996","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtha.2023.05.024_bib44","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2023.05.024_bib45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.12364","article-title":"The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies","volume":"93","author":"Membre","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.05.024_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0038-1655918","article-title":"Utilization of dilute Russell\u2019s viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids","volume":"77","author":"Pengo","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0037-1614453","article-title":"dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies","volume":"81","author":"Pengo","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib48","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1538-7836.2011.04212.x","article-title":"Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity","volume":"9","author":"Dienava-Verdoold","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.024_bib49","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40\u2013Arg43 in domain I of \u03b22-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"De Laat","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.024_bib50","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-\u03b22 glycoprotein I (\u03b22GPI) autoantibodies recognize an epitope on the first domain of \u03b22GPI","volume":"95","author":"Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.05.024_bib51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13317-014-0061-3","article-title":"The introduction of anti-phosphatidylserine\/prothrombin autoantibodies in the laboratory diagnostic process of anti-phospholipid antibody syndrome: 6 months of observation","volume":"5","author":"Fabris","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.jtha.2023.05.024_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/antib5020016","article-title":"The significance of anti-beta-2-glycoprotein I antibodies in antiphospholipid syndrome","volume":"5","author":"Brusch","year":"2016","journal-title":"Antibodies (Basel)"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623004397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623004397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:37:37Z","timestamp":1761536257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623004397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1538783623004397"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.05.024","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013\u03b22-glycoprotein I and anti-phosphatidylserine\/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}